In addition, inferior event free survival (median 0 vs. 6.8 months) was noted in MLL-PTD AML patients with DNMT3A mutations compared to those without DNMT3A mutations (Kao et al., 2015). This evidence concerns the gene KMT2A and acute myeloid leukemia.